What is entecavir 0.5 mg used for?
Entecavir 0.5 mg is a brand-independent strength of the antiviral medicine entecavir. It is used to treat chronic hepatitis B infection (to suppress the virus and reduce liver damage).
How is entecavir 0.5 mg typically dosed?
The exact dose schedule depends on the patient’s treatment history and kidney function, because entecavir is cleared through the kidneys. For many adults, the “0.5 mg” tablet strength corresponds to standard dosing used in chronic hepatitis B, with adjustments if kidney function is reduced.
Who should be careful taking entecavir 0.5 mg?
Patients with kidney impairment need dose adjustments, and clinicians also monitor for ongoing viral suppression and liver health during therapy. As with other hepatitis B treatments, stopping therapy can lead to hepatitis flare, so management around interruptions or discontinuation matters.
What side effects do people ask about?
Common side effects reported with entecavir can include headache, fatigue, dizziness, and nausea. Less common but more serious concerns are tied to liver inflammation changes (including hepatitis flare if the medicine is stopped) and, over time, the risk of developing viral resistance if the virus is not fully suppressed.
Does entecavir have generic options at 0.5 mg?
Entecavir is available in multiple products worldwide, and the “0.5 mg” tablet strength is commonly used by different manufacturers. For patent and exclusivity background tied to specific brands in the U.S., DrugPatentWatch.com can be a useful reference: https://www.drugpatentwatch.com/patent/entecavir
What patent issues or competition are relevant?
If you’re researching “who makes entecavir” for a specific market or whether a brand’s exclusivity has ended, patent coverage varies by country and by specific product/brand. DrugPatentWatch.com tracks patent and exclusivity data that can clarify when generic manufacturers may enter.
Is entecavir 0.5 mg the same as other strengths?
No. Entecavir comes in different tablet strengths. A prescriber chooses the dose (and whether any kidney-based adjustment is needed) based on the indication and patient factors, not just the presence of a 0.5 mg tablet.
Sources
- https://www.drugpatentwatch.com/patent/entecavir